Indatuximab ravtansine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Indatuximab ravtansine
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target SDC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1]

It is being investigated as part of a treatment for multiple myeloma.[1]

Clinical trials[edit]

Multiple Myeloma[edit]

Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.[1] Follow up data reported "encouraging efficacy" in Dec 2014.[2]

Other[edit]

As of December 2014 it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.[2]

Mechanism of action[edit]

CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.[1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.

See also[edit]

  • ImmunoGen, more on DM1/DM4 and the linker used in Indatuximab ravtansine
  • Syndecan 1, the protein encoded by SDC1.

References[edit]

  1. ^ a b c d e Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
  2. ^ a b Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone